Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by BearDownAZon Jun 25, 2013 4:22pm

174 Views

Post# 21572068

200 day moving average

Thanks Forbes for pointing out that we just recently crossed the 200-day moving average of $2.44. Were we not already above the moving average before the post-Zenith spin of plunge? It would have been nice if the article had mentioned, "Oh by the way, long-awaited results from the ASSURE IVUS trial are expected any day now."

https://www.forbes.com/sites/dividendchannel/2013/06/25/bullish-two-hundred-day-moving-average-cross-rvx/

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity